Elucidation of the neurobiology of depression: Insights from a novel genetic animal model

Progress in Neurobiology

Volumn 62, Issue 4, 2000, Pages 353-378

  Yadid, Gal ^a   Nakash, Rachel ^a   Deri, Ilana ^a   Tamar, Grin ^a   Kinor, Noa ^a   Gispan, Iris ^a   Zangen, Abraham ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG BIOAVAILABILITY; DRUG MECHANISM; LEARNED HELPLESSNESS; MOTOR ACTIVITY; NEUROBIOLOGY; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; SEROTONINERGIC SYSTEM; STRESS;

ANIMALS; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; HUMANS;

EID: 0034335358     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-0082(00)00018-6     Document Type: Review

References (270)

1. Adell A., Garcia-Marquez C., Armario A., Gelpi E. Chronic stress increases serotonin and noradrenaline in rat brain and sensitizes their responses to a further acute stress. J. Neurochem. 50:1988;1678-1681.
2. Akiskal H.S. Mood disorders: introduction and overview. Kaplan H.I., Sadock B.J. Comprehensive Textbook of Psychiatry. 1995;1067-1068 Williams & Wilkins, Baltimore.
3. Alpers H.S., Himwich H.E. The effects of chronic imipramine administration on rat brain levels of serotonin, 5-hydroxyindoleacetic acid, norepinephrine and dopamine. J. Pharmacol. Exp. Ther. 180:1972;531-538.
4. Amalric M., Cline E.J., Martinez J.L.J., Bloom F.E., Koob G.F. Rewarding properties of beta-endorphin as measured by conditioned place preference. Psychopharmacology (Berl.). 91:1987;14-19.
5. Anderson D.C., Cole J., McVaugh W. Variations in unsignaled inescapable preshock as determinants of responses to punishment. J. Comp. Physiol. Psychol. 65:(Suppl.):1968;17.
6. Anderson I.M., Tomenson B.M. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J. Psychopharmacology. 4:1994;238-249.
7. Angst J. Epidemiology of depression. Psychopharmacology (Berl.). 106:(Suppl.):1992;S71-S74.
8. Aprison M.H., Hingtgen J.N., Nagayama H. Testing a new theory of depression with an animal model: neurochemical-behavioural evidence for postsynaptic serotonergic receptor involvement. Langer S.Z., Takahashi R., Segawa T., Briley M. New Vistas in Depression. 1982;171-178 Pergamon Press, New York.
9. 2 and beta-adrenergic receptor binding sites in the brain of suicide victims. Arch. Gen. Psychiatry. 47:1990;1038-1047.
10. Arango V., Underwood M.D., Mann J.J. Alterations in monoamine receptors in the brain of suicide victims. J. Clin. Psychopharmacol. 12:1992;8S-12S.
11. 3H -LSD) in the blood platelets of depressed patients. Life Sci. 44:1989;725-734.
12. 2 receptors in suicide victims. Biol. Psychiatry. 35:1994;457-463.
13. Artigas F., Perez V., Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry. 51:1994;248-251.
14. Asberg M., Bertilsson L., Martensson B., Scalia-Tomba G.P., Thoren P., Traskman-Bendz L. CSF monoamine metabolites in melancholia. Acta Psychiatr. Scand. 69:1984;201-219.
15. Ascher J.A., Cole J.O., Colin J.N., Feighner J.P., Ferris R.M., Fibiger H.C., Golden R.N., Martin P., Potter W.Z., Richelson E. Bupropion: a review of its mechanism of antidepressant activity. J. Clin. Psychiatry. 56:1995;395-401.
16. Babington R.G. Antidepressives and the kindling effect. Fielding S., Lal H. Antidepressants. 1975;113-124 Futura, Mount Kisco, New York.
17. Babington R.G., Wedeking P.W. The pharmacology of seizures induced by sensitization with low intensity brain stimulation. Pharmacol. Biochem. Behav. 1:1973;461-467.
18. Baldessarini R.J. Current status of antidepressants: clinical pharmacology and therapy. J. Clin. Psychiatry. 50:1989;117-126.
19. Bals-Kubik R., Shippenberg T.S., Herz A. Involvement of central u and d opioid receptors in mediating the reinforcing effects of β-endorphin in the rat. Eur. J. Pharmacol. 175:1990;63-69.
20. Baltzer V., Weiskrantz L. Antidepressant agents and reversal of diurnal activity cycles in the rat. Biol. Psychiatry. 10:1973;199-209.
21. Banki C.M. 5-Hydroxytryptamine content of the whole blood in psychiatric illness and alcoholism. Acta Psychiatr. Scand. 57:1978;232-238.
22. Baraban J.M., Aghajanian G.K. Suppression of firing activity of 5-HT neurons in the dorsal raphe by α-adrenoceptor antagonists. Neuropharmacology. 19:1980;355-363.
23. Barrett R.J., White D.K. Reward system depression following chronic amphetamine: antagonism by haloperidol. Pharmacol. Biochem. Behav. 13:1980;555-559.
24. Baumgarten H.G., Bjorklund L., Lachenmayer L., Nobin A. Evaluation of the effect of 5,7-dihydroxytryptamine on serotonin and dopamine neurons in the rat CNS. Acta Physiol. Scand. (Suppl.). 391:1971;1-19.
25. Bel N., Artigas F. In vivo effects of the simultaneous blockade of serotonin and norepinephrine transporters on serotonergic function. Microdialysis studies. J. Pharmacol. Exp. Ther. 278:1996;1064-1072.
26. Benca R.M., Overstreet D.E., Gilliland M.A., Russell D., Bergmann B.M., Obermeyer W.H. Increased basal REM sleep but no difference in dark induction or light suppression of REM sleep in Flinders rats with cholinergic supersensitivity. Neuropsychopharmacology. 15:1996;45-51.
27. Benloucif S., Keegan M.J., Galloway M.P. Serotonin-facilitated dopamine release in vivo: pharmacological characterization. J. Pharmacol. Exp. Ther. 265:1993;373-377.
28. 2 antagonists. Behav. Pharmacol. 1:1989;355-363.
29. Beskow J. Depression and suicide. Pharmacopsychiatry. 23:(Suppl.):1990;3-8.
30. Beskow J., Gottfries C.G., Roos B.E., Winblad B. Determination of monoamine and monoamine metabolites in the human brain: postmortem studies in a group of suicides and in a control group. Acta Psychiatr. Scand. 53:1976;7-20.
31. Black P.M., Ballantine H.T.J., Carr D.B., Beal M.F., Martin J.B. Beta-endorphin and somatostatin concentrations in the ventricular cerebrospinal fluid of patients with affective disorder. Biol. Psychiatry. 21:1986;1077-1081.
32. Blier P., Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J. Clin. Psychopharmacol. 15:1995;217-222.
33. Blier P., de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15:1994;220-226.
34. Blier P., de Montigny C., Chaput Y. A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. J. Clin. Psychiatry. 51:(Suppl.):1990;14-20.
35. Bloom F.E., Rossier J., Battenberg E.L., Bayon A., French E., Henriksen S.J., Siggins G.R., Segal D., Browne R., Ling N., Guillemin R. Beta-endorphin: cellular localization, electrophysiological and behavioral effects. Adv. Biochem. Psychopharmacol. 18:1978;89-109.
36. Borsini F., Meli A. Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology (Berl.). 94:1988;147-160.
37. Breiter H.C., Gollub R.L., Weisskoff R.M., Kennedy D.N., Makris N., Berke J.D., Goodman J.M., Kantor H.L., Gastfriend D.R., Riorden J.P., Mathew R.T., Rosen B.R., Hyman S.E. Acute effects of cocaine on human brain activity and emotion. Neuron. 19:1997;591-611.
38. Briley M.S., Langer S.Z., Raisman R., Sechter D., Zarifian E. Tritiated imipramine binding sites are decreased in platelets of untreated depressed patients. Science. 209:1980;303-305.
39. Briner K., Dodel R.C. New approaches to rapid onset antidepressants. Curr. Pharm. Des. 4:1998;291-302.
40. Brown R.S., Bottomley W.K. Utilization and mechanism of action of tricyclic antidepressants in the treatment of chronic facial pain: a review of the literature. Anesth. Prog. 37:1990;223-229.
41. Brown R., Kocsis J.H., Caroff S., Amsterdam J., Winokur A., Stokes P.E., Frazer A. Differences in nocturnal melatonin secretion between melancholic depressed patients and control subjects. Am. J. Psychiatry. 142:1985;811-816.
42. Burke M.J., Preskorn S.H. Short-term treatment of mood disorders with standard antidepressants. Bloom F.E., Kupfer D.J. Psychopharmacology: The Fourth Generation of Progress. 1995;1053-1067 Raven, New York.
43. Bushnell P.J., Levin E.D., Overstreet D.H. Spatial working and reference memory in rats bred for autonomic sensitivity to cholinergic stimulation: acquisition, accuracy, speed, and effects of cholinergic drugs. Neurobiol. Learn Mem. 63:1995;116-132.
44. Caccia S., Anelli M., Codegoni A.M., Fracasso C., Garattini S. The effects of single and repeated anorectic doses of 5-hydroxytryptamine uptake inhibitors on indole levels in rat brain. Br. J. Pharmacol. 110:1993;355-359.
45. Cairncross K.D., Cox B. A new model for the detection of antidepressant drugs: Olfactory bulbectomy in the rat compared with existing models. J. Pharmacol. Methods. 1:1978;131-143.
46. Cairncross K.D., Cox B., Forster C., Wren A.F. Olfactory projection systems, drugs and behaviour: a review. Psychoneuroendocrinology. 4:1979;253-272.
47. Cairncross K.D., Wren A., Cox B., Schnieden H. Effects of olfactory bulbectomy and domicile on stress-induced corticosterone release in the rat. Physiol. Behav. 19:1977;485-487.
48. 3 antagonist on drug-induced stimulation of dopamine release. Eur. J. Pharmacol. 164:1989;515-519.
49. Cheeta S., Ruigt G., van Proosdij J., Willner P. Changes in sleep architecture following chronic mild stress. Biol. Psychiatry. 41:1997;419-427.
50. Cheetham S.C., Crompton M.R., Czudek C., Horton R.W., Katona C.L., Reynolds G.P. Serotonin concentrations and turnover in brains of depressed suicides. Brain Res. 502:1989;332-340.
51. 2 receptor binding sites in depressed suicide victims. Brain Res. 443:1988;272-280.
52. 1 binding sites in depressed suicides. Psychopharmacology (Berl.). 102:1990;544-548.
53. 3 receptor by 1-phenylbiguanide increases dopamine release in the rat nucleus accumbens. Brain Res. 543:1991;354-357.
54. Chung M.Y., Kim D.G., Yoo K.J., Hong S.S. Regional differences in the levels of biogenic amines and their metabolites in rat brain after tricyclic antidepressant treatments. Yonsei. Med. J. 34:1993;266-277.
55. Cohen M.R., Pickar D., Extein I., Gold M.S., Sweeney D.R. Plasma cortisol and beta-endorphin immunoreactivity in nonmajor and major depression. Am. J. Psychiatry. 141:1984;628-632.
56. Commissiong J.W. Monoamine metabolites: their relationship and lack of relationship to monoaminergic neuronal activity. Biochem. Pharmacol. 34:1985;1127-1131.
57. Coppen A., Turner P., Rowsell A.R., Padgham C. 5-Hydroxytryptamine (5-HT) in the whole-blood of patients with depressive illness. Postgrad. Med. J. 52:1976;156-158.
58. Corona G.L., Cucchi M.L., Santagostino G., Frattini P., Zerbi F., Fenoglio L., Savoldi F. Blood noradrenaline and 5-HT levels in depressed women during amitriptyline or lithium treatment. Psychopharmacology (Berl.). 77:1982;236-241.
59. Cowen P.J., Gadhvi H., Gosden B., Kolakowska T. Responses of prolactin and growth hormone to L-tryptophan infusion: effects in normal subjects and schizophrenic patients receiving neuroleptics. Psychopharmacology (Berl.). 86:1985;164-169.
60. Cummings J.L. The neuroanatomy of depression. J. Clin. Psychiatry. 11:(Suppl.):1993;14-20.
61. Dalayeun J.F., Nores J.M., Bergal S. Physiology of beta-endorphins. A close-up view and a review of the literature. Biomed. Pharmacother. 47:1993;311-320.
62. D'Aquila P.S., Brain P., Willner P. Effects of chronic mild stress on performance in behavioural tests relevant to anxiety and depression. Physiol. Behav. 56:1994;861-867.
63. Darko D.F., Irwin M.R., Risch S.C., Gillin J.C. Plasma β-endorphin and natural killer cell activity in major depression: a preliminary study. Psychiatry Res. 43:1992;111-119.
64. Darko D.F., Risch S.C., Gillin J.C., Golshan S. Association of b-endorphin with specific clinical symptoms of depression. Am. J. Psychiatry. 149:1992;1162-1167.
65. Davis R., Whittington R., Bryson H.M. Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs. 53:1997;608-636.
66. de Boer T. The pharmacologic profile of mirtazapine. J. Clin. Psychiatry. 57:(Suppl. 4):1996;19-25.
67. 3 receptors. J. Neurosci. 18:1998;6528-6538.
68. Delgado P.L., Charney D.S., Price L.H., Landis H., Heninger G.R. Neuroendocrine and behavioral effect of dietary tryptophan restriction in healthy subjects. Life Sci. 45:1990;2323-2332.
69. Delgado P.L., Miller H.L., Salomon R.M., Licinio J., Heninger G.R., Gelenberg A.J., Charney D.S. Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol. Bull. 29:1993;389-396.
70. 1A receptor antagonists. Psychopharmacology (Berl.). 119:1995;47-54.
71. Devaud L.L., Hollingsworth E.B., Cooper B.R. Alterations in extracellular and tissue levels of biogenic amines in rat brain induced by the serotonin2 receptor antagonist, ritanserin. J. Neurochem. 59:1992;1459-1466.
72. 3H ]paroxetine binding and serotonin content of rat brain: absence of changes following antidepressant treatments. Eur. J. Pharmacol. 235:1993;137-142.
73. di Chiara G., Acquas E., Tanda G., Cadoni C. Drugs of abuse: biochemical surrogates of specific aspects of natural reward? Biochem. Soc. Symp. 59:1993;65-81.
74. di Mascio M., di Giovanni G., di M.V., Esposito E. Decreased chaos of midbrain dopaminergic neurons after serotonin denervation. Neuroscience. 92:1999;237-243.
75. di Mascio M., di Giovanni G., di M.V., Esposito E. Reduced chaos of interspike interval of midbrain dopaminergic neurons in aged rats. Neuroscience. 89:1999;1003-1008.
76. Dubovsky S.L. Beyond the serotonin reuptake inhibitors: rationales for the development of new serotonergic agents. J. Clin. Psychiatry. 55:(Suppl.):1994;34-44.
77. Einon D., Morgan M.J., Sahakian B.J. The development of intersession habituation and emergence in socially reared and isolated rats. Dev. Psychobiol. 8:1975;553-559.
78. Everett G.M. The DOPA response potentiation test and its use in screening for antidepressant drugs. Garattini S., Dukes M.N.G. Antidepressant drug. 1967;164-167 Excerpta Medica, Amsterdam.
79. Feldman R.S., Meyer J.S., Quenzer L.F. Affective disorders. Feldman R.S., Meyer J.S., Quenzer L.F. Principles of Neuropharmacology. 1997;819-861 Sinauer, Sunderland.
80. Fields H.L., Heinricher M.M., Mason P. Neurotransmitters in nociceptive modulatory circuits. Annu. Rev. Neurosci. 14:1991;219-245.
81. Foley K.M., Kourides I.A., Inturrisi C.E., Kaiko R.F., Zaroulis C.G., Posner J.B., Houde R.W., Li C.H. β-Endorphin: analgesic and hormonal effects in humans. Proc. Natl. Acad. Sci. USA. 76:1979;5377-5381.
82. Fornal C., Radulovacki M. Sleep suppressant action of fenfluramine in rats. Part I: Relation to postsynaptic serotonergic stimulation. J. Pharmacol. Exp. Ther. 225:1983;667-674.
83. France R.D., Urban B.J. Cerebrospinal fluid concentrations of β-endorphin in chronic low back pain patients. Psychosomatics. 32:1991;72-77.
84. Frazer A. Pharmacology of antidepressants. J. Clin. Psychopharmacol. 17:1997;2S-18S.
85. Galloway M.P. Regulation of dopamine and serotonin synthesis by acute administration of cocaine. Synapse. 6:1990;63-72.
86. Galloway M.P., Wolf M.E., Roth R.H. Regulation of dopamine synthesis in the medial prefrontal cortex is mediated by release modulating autoreceptors: studies in vivo. J. Pharmacol. Exp. Ther. 236:1986;689-698.
87. Garber J., Miller W.R., Seaman S.F. Learned helplessness, stress and the depressive disorders. Depue R.A. The Psychobiology of the Depressive Disorders: Implications for the Effects of Stress. 1979;335-363 Academic Press, New York.
88. Gerner R.H., Catlin D.H., Gorelick D.A., Hui K.K., Li C.H. β-Endorphin: intravenous infusion causes behavioral change in psychiatric inpatients. Arch. Gen. Psychiatry. 37:1980;642-647.
89. Gershon E.S., Berrettini W., Nurnberger J.I., Goldin L.R. Genetics of affective illness. Meltzer H.Y. Psychopharmacology: The Third Generation of Progress. 1987;481-492 Raven, New York.
90. Goddard G.V., McIntyre D.C., Leech C.K. A permanent change in brain function resulting from daily electrical stimulation. Exp. Neurol. 25:1969;295-330.
91. Goodwin G.M., Austin M.P., Curran S.M., Ross M., Murray C., Prentice N., Ebmeier K.P., Bennie J., Carroll S., Dick H. The elevation of plasma b-endorphin levels in major depression. J. Affect. Disord. 29:1993;281-289.
92. Gorka Z., Moryl E., Papp M. Effect of chronic mild stress on circadian rhythms in the locomotor activity in rats. Pharmacol. Biochem. Behav. 54:1996;229-234.
93. Greenberg P.E., Stiglin L.E., Finkelstein S.N., Berndt E.R. Depression: a neglected major illness. J. Clin. Psychiatry. 54:1993;419-424.
94. Gross-Isseroff R., Israeli M., Biegon A. Autoradiographic analysis of tritiated imipramine binding in the human brain postmortem: effects of suicide. Arch. Gen. Psychiatry. 46:1989;237-241.
95. Guan X.M., McBride W.J. Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release. Brain Res. Bull. 23:1989;541-547.
96. 2 and 5-HT1A receptors. Neuropharmacology. 25:1986;1307-1313.
97. Hamba M. Effects of lesion and stimulation of rat hypothalamic arcuate nucleus on the pain system. Brain Res. Bull. 21:1988;757-763.
98. Hatotani N., Nomura J. Changes of brain monoamines in the animal model for depression. Langer S.Z., Takahashi R., Segawa T., Briley M. New Vistas in Depression. 1982;65-72 Pergamon Press, New York.
99. Hinde R.A., Leighton-Shapiro M.E., McGinnis L. Effects of various types of separation experience on rhesus monkeys 5 months later. J. Child Psychol. Psychiatry. 19:1978;199-211.
100. Horowitz Z.P. Selective block or rat mouse killing by antidepressants. Life Sci. 4:1965;1909-1912.
101. 3H ]imipramine recognition sites in rat brain by chronic treatment with antidepressants. Eur. J. Pharmacol. 138:1987;159-168.
102. Iyengar S., Kim H.S., Marien M.R., McHugh D., Wood P.L. Modulation of mesolimbic dopaminergic projections by b-endorphin in the rat. Neuropharmacology. 28:1989;123-128.
103. Jacobs B.L., Azmitia E.C. Structure and function of the brain serotonin system. Physiol. Rev. 72:1992;165-229.
104. 3H ]dopamine via reversal of the dopamine transporter in rat striatum and nucleus accumbens: a comparison with release elicited by potassium, N-methyl-D-aspartic acid, glutamic acid and D-amphetamine. J. Pharmacol. Exp. Ther. 262:1992;356-364.
105. Janowsky D.S., Overstreet D.H. The cholinergic hypothesis of depression. Psychopharmacology: The Fourth Generation of Progress. 1995;944-957 Raven, New York.
106. Janowsky D.S., Overstreet D.H., Nurnberger J.I.J. Is cholinergic sensitivity a genetic marker for the affective disorders? Am. J. Med. Genet. 54:1994;335-344.
107. Janowsky D.S., Risch S.C. Cholinomimetic and anticholinergic drugs used to investigate an acetylcholine hypothesis of affective disorders and stress. Drug Dev. Res. 4:1984;125-142.
108. Janowsky D.S., Risch C., Parker D., Huey L., Judd L. Increased vulnerability to cholinergic stimulation in affective-disorder patients. Psychopharmacol. Bull. 16:1980;29-31.
109. 3 receptor agonist 2-methylserotonin on the release of dopamine in the nucleus accumbens: an in vivo chronocoulometric study. Brain Res. 513:1990;156-160.
110. Johnson S.W., North R.A. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J. Neurosci. 12:1992;483-488.
111. Katz R.J. Animal models and human depressive disorders. Neurosci. Biobehav. Rev. 5:1981;231-246.
112. Katz R.J., Roth K.A., Carroll B.J. Acute and chronic stress effects on open field activity in the rat: implications for a model of depression. Neurosci. Biobehav. Rev. 5:1981;247-251.
113. Katz R.J., Sibel M. Animal model of depression: tests of three structurally and pharmacologically novel antidepressant compounds. Pharmacol. Biochem. Behav. 16:1982;973-977.
114. Katz R.J., Sibel M. Further analysis of the specificity of a novel animal model of depression-effects of an antihistaminic, antipsychotic and anxiolytic compound. Pharmacol. Biochem. Behav. 16:1982;979-982.
115. Kaufman I.C., Rosenblum L.A. The reaction to separation in infant monkeys: anaclitic depression and conservation-withdrawal. Psychosom. Med. 29:1967;648-675.
116. Kind P., Sorensen J. The costs of depression. Int. Clin. Psychopharmacol. 7:1993;191-195.
117. King R., Barchas J.D., Huberman B.A. Chaotic behavior in dopamine neurodynamics. Proc. Natl. Acad. Sci. USA. 81:1984;1244-1247.
118. Klinger E., Barta S.G., Kemble E.D. Cyclic activity changes during extinction in rats: a potential model of depression. Anim. Learn Behav. 2:1974;313-316.
119. Kokkinidis L., Zacharko R.M. Response sensitization and depression following long-term amphetamine treatment in a self-stimulation paradigm. Psychopharmacology (Berl.). 68:1980;73-76.
120. Koob G.F. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends. Pharmacol. Sci. 13:1992;177-184.
121. Koob G.F., Bloom F.E. Cellular and molecular mechanisms of drug dependence. Science. 242:1988;715-723.
122. Kuhar M.J., Ritz M.C., Boja J.W. The dopamine hypothesis of the reinforcing properties of cocaine. Trends. Neurosci. 14:1991;299-302.
123. Lantos T.A., Gorcs T.J., Palkovits M. Immunohistochemical mapping of neuropeptides in the premamillary region of the hypothalamus in rats. Brain Res. Rev. 20:1995;209-249.
124. Lassen J.B., Lund J., Sondergaard I. Central and peripheral 5-HT uptake in rats treated chronically with femoxetine, paroxetine, and chlorimipramine. Psychopharmacology (Berl.). 68:1980;229-233.
125. Le Quan-Bui K.H., Plaisant O., Leboyer M., Gay C., Kamal L., Devynck M.A., Meyer P. Reduced platelet serotonin in depression. Psychiatry Res. 13:1984;129-139.
126. Leith N.J., Barrett R.J. Amphetamine and the reward system: evidence for tolerance and post-drug depression. Psychopharmacologia. 46:1976;19-25.
127. Leith N.J., Barrett R.J. Effects of chronic amphetamine or reserpine on self-stimulation responding: animal model of depression? Psychopharmacology (Berl.). 72:1980;9-15.
128. Lesch K.P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., Benjamin J., Muller C.R., Hamer D.H., Murphy D.L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 274:1996;1527-1531.
129. Loh H.H., Tseng L.F., Wei E., Li C.H. Beta-endorphin is a potent analgesic agent. Proc. Natl. Acad. Sci. USA. 73:1976;2895-2898.
130. Maes M., Meltzer H.Y. The serotonin hypothesis of major depression. Bloom F.E., Kupfer D.J. Psychopharmacology. The Fourth Generation of Progress. 1995;933-944 Raven, New York.
131. Magni G. The use of antidepressants in the treatment of chronic pain. A review of the current evidence. Drugs. 42:1991;730-748.
132. Maier S.F. Learned helplessness and animal models of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry. 8:1984;435-446.
133. Maier S.F., Grahn R.E., Watkins L.R. 8-OH-DPAT microinjected in the region of the dorsal raphe nucleus blocks and reverses the enhancement of fear conditioning and interference with escape produced by exposure to inescapable shock. Behav. Neurosci. 109:1995;404-412.
134. Maier S.F., Seligman M.E. Learned helplessness. Theory and evidence. J. Exp. Psychol. 105:1976;3-46.
135. Malick J.B. Yohimbine potentiation as a predictor of antidepressant action. Enna S.J., Malick J.B., Richelson E. Antidepressants: Neurochemical, Behavioral and Clinical Perspectives. 1981;141-155 Raven, New York.
136. Mann, J.J., Arango, V., Marzuk, P.M., Theccanat, S., Reis, D.J., 1989. Evidence for the 5-HT hypothesis of suicide. A review of post-mortem studies. Br. J. Psychiatry Suppl., 7-14.
137. Mansour A., Fox C.A., Burke S., Meng F., Thompson R.C., Akil H., Watson S.J. u, d, and k Opioid receptor mRNA expression in the rat CNS: an in situ hybridization study. J. Comp. Neurol. 350:1994;412-438.
138. Matheson G.K., Knowles A., Guthrie D., Gage D., Weinzapfel D., Blackbourne J. Actions of serotonergic agents on hypothalamic-pituitary-adrenal axis activity in the rat. Gen. Pharmacol. 29:1997;823-828.
139. Matsubara S., Arora R.C., Meltzer H.Y. Serotonergic measures in suicide brain: 5-HT1A binding sites in frontal cortex of suicide victims. J. Neural Transm. Gen. Sect. 85:1991;181-194.
140. McKinney W.T.J., Bunney W.E.J. Animal model of depression. Part I: Review of evidence - implications for research. Arch. Gen. Psychiatry. 21:1969;240-248.
141. Meltzer H.Y., Arora R.C. Platelet markers of suicidality. Ann. NY Acad. Sci. 487:1986;271-280.
142. Meltzer H.Y., Arora R.C., Jackman H., Pscheidt G., Smith M.D. Platelet monoamine oxidase and plasma amine oxidase in psychiatric patients. Schizophr. Bull. 6:1980;213-219.
143. Meltzer H.Y., Lowy M.T. The serotonin hypothesis of depression. Meltzer H.Y., Lowy M.T. Psychopharmacology: The Third Generation of Progress. 1987;513-526 Raven, New York.
144. Mendels J., Reimherr F., Marcus R.N., Roberts D.L., Francis R.J., Anton S.F. A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients. J. Clin. Psychiatry. 56:1995;30-36.
145. Miyauchi T., Kitada Y., Satoh S. Effects of acutely and chronically administered antidepressants on the brain regional 3-methoxy-4-hydroxyphenylethyleneglycol sulfate in the forced swimming rat. Life Sci. 29:1981;1921-1928.
146. Monroe P.J., Hawranko A.A., Smith D.L., Smith D.J. Biochemical and pharmacological characterization of multiple β-endorphinergic antinociceptive systems in the rat periaqueductal gray. J. Pharmacol. Exp. Ther. 276:1996;65-73.
147. Montgomery S.A. Reboxetine: additional benefits to the depressed patient. J. Psychopharmacol. 11:1997;S9-15.
148. Montgomery S.A., Doogan D.P., Burnside R. The influence of different relapse criteria on the assessment of long-term efficacy of sertraline. Int. Clin. Psychopharmacol. 6 Suppl 2:1991;37-46.
149. Morley J.E. Neuropeptide regulation of appetite and weight. Endocr. Rev. 8:1987;256-287.
150. Muck-Seler D., Jakovljevic M., Deanovic Z. Platelet serotonin in subtypes of schizophrenia and unipolar depression. Psychiatry Res. 38:1991;105-113.
151. Naber D., Pickar D., Post R.M., van Kammen D.P., Waters R.N., Ballenger J.C., Goodwin F.K., Bunney W.E.J. Endogenous opioid activity and b-endorphin immunoreactivity in CSF of psychiatric patients and normal volunteers. Am. J. Psychiatry. 138:1981;1457-1462.
152. Nagayama H., Hingtgen J.N., Aprison M.H. Pre- and postsynaptic serotonergic manipulations in an animal model of depression. Pharmacol. Biochem. Behav. 13:1980;575-579.
153. Nagayama H., Hingtgen J.N., Aprison M.H. Postsynaptic action by four antidepressive drugs in an animal model of depression. Pharmacol. Biochem. Behav. 15:1981;125-130.
154. Nahshoni E., Aizenberg D., Sigler M., Strasberg B., Adler E.J., Weizman A. Analysis of heart rate variability using leinear and non-linear techniques (chaos theory) in patients with major depressive disorder undergoing ECT. World Psychiatric Association, Thematic Conference. The Synthesis between Psychopharmacology and Psychotherapy :1995;29.
155. Naitoh H., Nomura S., Kunimi Y., Yamaoka K. "Swimming-induced head twitching" in rats in the forced swimming test induced by overcrowding stress: a new marker in the animal model of depression? Keio. J. Med. 41:1992;221-224.
156. Nelson J.C. Safety and tolerability of the new antidepressants. J. Clin. Psychiatry. 58:(Suppl. 6):1997;26-31.
157. Nestler E.J. Antidepressant treatments in the 21st century. Biol. Psychiatry. 44:1998;526-533.
158. Niswender C.M., Sanders-Bush E., Emeson R.B. Identification and characterization of RNA editing events within the 5-HT2C receptor. Ann. NY Acad. Sci. 861:1998;38-48.
159. Olson G.A., Olson R.D., Kastin A.J. Endogenous opiates: 1992. Peptides. 14:1993;1339-1378.
160. Ormel, J., von Korff, M., Ustun, T.B., et al., 1992. The association of psychological illness and functional disability: replication across 15 general health care settings in a multicentre, international study.
161. Overstreet D.H. Selective breeding for increased cholinergic function: development of a new animal model of depression. Biol. Psychiatry. 21:1986;49-58.
162. Overstreet D.H. The Flinders sensitive line rats: a genetic animal model of depression. Neurosci. Biobehav. Rev. 17:1993;51-68.
163. Overstreet D.H., Janowsky D.S., Gillin J.C., Shiromani P.J., Sutin E.L. Stress-induced immobility in rats with cholinergic supersensitivity. Biol. Psychiatry. 21:1986;657-664.
164. Overstreet D.H., Janowsky D.S., Pucilowski O., Rezvani A.H. Swim test immobility co-segregates with serotonergic but not cholinergic sensitivity in cross-breeds of Flinders Line rats. Psychiatr. Genet. 4:1994;101-107.
165. Overstreet D.H., Pucilowski O., Rezvani A.H., Janowsky D.S. Administration of antidepressants, diazepam and psychomotor stimulants further confirms the utility of Flinders Sensitive Line rats as an animal model of depression. Psychopharmacology (Berl.). 121:1995;7-37.
166. Overstreet D.H., Rezvani A.H., Janowsky D.S. Genetic animal models of depression and ethanol preference provide support for cholinergic and serotonergic involvement in depression and alcoholism. Biol. Psychiatry. 31:1992;919-936.
167. Overstreet D.H., Rezvani A.H., Pucilowski O., Gause L., Janowsky D.S. Rapid selection for serotonin-1A sensitivity in rats. Psychiatr. Genet. 4:1994;57-62.
168. Overstreet D.H., Russell R.W. Selective breeding for diisopropyl fluorophosphate-sensitivity: behavioural effects of cholinergic agonists and antagonists. Psychopharmacology (Berl.). 78:1982;150-155.
169. Overstreet D.H., Russell R.W., Crocker A.D., Gillin J.C., Janowsky D.S. Genetic and pharmacological models of cholinergic supersensitivity and affective disorders. Experientia. 44:1988;465-472.
170. Overstreet D.H., Steiner M. Genetic and environmental models of stress-induced depression in rats. Stress Medicine. 14:(4):1998;261-268.
171. Owen F., Chambers D.R., Cooper S.J., Crow T.J., Johnson J.A., Lofthouse R., Poulter M. Serotonergic mechanisms in brains of suicide victims. Brain Res. 362:1986;185-188.
172. Papolos D.F., Yu Y.M., Rosenbaum E., Lachman H.M. Modulation of learned helplessness by 5-hydroxytryptamine 2A receptor antisense oligodeoxynucleotides. Psychiatry Res. 63:1996;197-203.
173. Papp M., Klimek V., Willner P. Effects of imipramine on serotonergic and β-adrenergic receptor binding in a realistic animal model of depression. Psychopharmacology (Berl.). 114:1994;309-314.
174. 2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine. Psychopharmacology (Berl.). 115:1994;441-446.
175. Pare C.M., Yeung D.P., Price K., Stacey R.S. 5-Hydroxytryptamine, noradrenaline, and dopamine in brainstem, hypothalamus, and caudate nucleus of controls and of patients committing suicide by coal-gas poisoning. Lancet. 2:1969;133-135.
176. Parker R.M., Barnes J.M., Ge J., Barber P.C., Barnes N.M. Autoradiographic distribution of [3H]-(S)-zacopride-labelled 5-HT3 receptors in human brain. J. Neurol. Sci. 144:1996;119-127.
177. Parsons L.H., Justice J.B.J. Perfusate serotonin increases extracellular dopamine in the nucleus accumbens as measured by in vivo microdialysis. Brain Res. 606:1993;195-199.
178. Perry E.K., Marshall E.F., Blessed G., Tomlinson B.E., Perry R.H. Decreased imipramine binding in the brains of patients with depressive illness. Br. J. Psychiatry. 142:1983;188-192.
179. Petty F., Kramer G., Wilson L. Prevention of learned helplessness: in vivo correlation with cortical serotonin. Pharmacol. Biochem. Behav. 43:1992;361-367.
180. Phillips A., Pfaus J.G., Blaha C.D. Willner P., Scheel-Kruger J. The Mesolimbic Dopamine System: From Motivation to Action. 1991;199-224 Wiley, Chichester.
181. Pitts W.M., Fann W.E., Halaris A.E., Dressler D.M., Sajadi C., Snyder S., Ilaria R.L. Bupropion in depression: a tri-center placebo-controlled study. J. Clin. Psychiatry. 44:1983;95-100.
182. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol. 47:1978;379-391.
183. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 229:1977;327-336.
184. Porsolt R.D., Bertin A., Jalfre M. Behavioural despair in rats and mice: strain differences and the effects of imipramine. Eur. J. Pharmacol. 51:1978;291-294.
185. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature. 266:1977;730-732.
186. Potter W.Z., Rudorfer M.V., Manji H. The pharmacologic treatment of depression. N. Engl. J. Med. 325:1991;633-642.
187. Pucilowski O., Overstreet D.H. Effect of chronic antidepressant treatment on responses to apomorphine in selectively bred rat strains. Brain Res. Bull. 32:1993;471-475.
188. Pucilowski O., Overstreet D.H., Rezvani A.H., Janowsky D.S. Chronic mild stress-induced anhedonia: greater effect in a genetic rat model of depression. Physiol. Behav. 54:1993;1215-1220.
189. Quintana J. Platelet serotonin and plasma tryptophan decreases in endogenous depression. Clinical, therapeutic, and biological correlations. J. Affect. Disord. 24:1992;55-62.
190. Quinton R.M. The increase in the toxicity of yohimbine induced by imipramine and other drugs in mice. Br. J. Pharmacol. 21:1963;51-66.
191. Reddy P.L., Khanna S., Subhash M.N., Channabasavanna S.M., Rao B.S. CSF amine metabolites in depression. Biol. Psychiatry. 31:1992;112-118.
192. Reite M., Short R., Seiler C., Pauley J.D. Attachment, loss, and depression. J. Child Psychol. Psychiatry. 22:1981;141-169.
193. Ressler K.J., Nemeroff C.B. Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol. Psychiatry. 46:1999;1219-1233.
194. Richelson E. Biological basis of depression and therapeutic relevance. J. Clin. Psychiatry. 52:(Suppl.):1991;4-10.
195. Richelson E., Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J. Pharmacol. Exp. Ther. 230:1984;94-102.
196. Risch S.C. β-Endorphin hypersecretion in depression: possible cholinergic mechanisms. Biol. Psychiatry. 17:1982;1071-1079.
197. Robinson T.E., Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res. Brain Res. Rev. 18:1993;247-291.
198. Rosellini R.A. Inescapable shock interferes with the acquisition of a free appetitive operant. Anim. Learn Behav. 6:1978;155-159.
199. Rosellini R.A., de Cola J.P. Inescapable shock interferes with the acquisition of a low-activity response in an appetitive context. Anim. Learn Behav. 9:1981;487-490.
200. Roy A., Pickar D., Linnoila M., Doran A.R., Ninan P., Paul S.M. Cerebrospinal fluid monoamine and monoamine metabolite concentrations in melancholia. Psychiatry Res. 15:1985;281-292.
201. Sacerdote P., Brini A., Mantegazza P., Panerai A.E. A role for serotonin and β-endorphin in the analgesia induced by some tricyclic antidepressant drugs. Pharmacol. Biochem. Behav. 26:1987;153-158.
202. Sahakian B.J., Robbins T.W., Iversen S.D. The effects of isolation rearing on exploration in the rat. Anim. Learn Behav. 5:1977;193-198.
203. Sahakian B.J., Robbins T.W., Morgan M.J., Iversen S.D. The effects of psychomotor stimulants on stereotypy and locomotor activity in socially-deprived and control rats. Brain Res. 84:1975;195-205.
204. Salamone J.D. The involvement of nucleus accumbens dopamine in appetitive and aversive motivation. Behav. Brain Res. 61:1994;117-133.
205. Sambunaris A., Hesselink J.K., Pinder R., Panagides J., Stahl S.M. Development of new antidepressants. J. Clin. Psychiatry. 58:(Suppl. 6):1997;40-53.
206. Sarrias M.J., Artigas F., Martinez E., Gelpi E., Alvarez E., Udina C., Casas M. Decreased plasma serotonin in melancholic patients: a study with clomipramine. Biol. Psychiatry. 22:1987;1429-1438.
207. Sartorius, N., et al., 1983. Depressive disorders in different cultures. Report on the WHO Collaborative Study on Standardized Assessment of Depressive Disorders. World Health Organization, Geneva.
208. Sartorius N., deGirolamo G., Andrews G., et al. Treatment of Mental Disorders: A Review of Effectiveness. 1993;American Psychiatric Press, Washington, DC.
209. Schatzberg A.F., Samson J.A., Bloomingdale K.L., Orsulak P.J., Gerson B., Kizuka P.P., Cole J.O., Schildkraut J.J. Toward a biochemical classification of depressive disorders. X. Urinary catecholamines, their metabolites, and D-type scores in subgroups of depressive disorders. Arch. Gen. Psychiatry. 46:1989;260-268. [published erratum appears in Arch. Gen. Psychiatry 1989 Sep;46(9):860].
210. Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. J. Neuropsychiatry Clin. Neurosci. 7:1995;524-533.
211. Schildkraut J., Orsulak P., Gudeman J., Schatzberg A., Rohde W., LaBrie L., Cahill J., Cole J., Frazier S. Norepinephrine metabolism in subtypes of depressive disorders. Shagass C., Gershon S., Friedhoff A. Psychopathology and Brain Dysfunction. 1997;125-138 Raven, New York.
212. Schildkraut J.J., Winokur A., Applegate C.W. Norepinephrine turnover and metabolism in rat brain after long-term administration of imipramine. Science. 168:1970;867-869.
213. Schiller G.D., Daws L.C., Overstreet D.H., Orbach J. Absence of anxiety in an animal model of depression with cholinergic supersensitivity. Brain Res. Bull. 26:1991;443-447.
214. Schultz W., Dayan P., Montague P.R. A neural substrate of prediction and reward. Science. 275:1997;1593-1599.
215. Sedlock M.L., Edwards D.J. Opposite effects of chronic imipramine treatment on brain and urine MHPG levels in the rat. Biol. Psychiatry. 20:1985;858-865.
216. Self D.W., Nestler E.J. Molecular mechanisms of drug reinforcement and addiction. Annu. Rev. Neurosci. 18:1995;463-495.
217. Seligman M.E. Helplessness: On Depression, Development and Death. 1975;Freeman, San Francisco.
218. Seligman M.E., Beagley G. Learned helplessness in the rat. J. Comp. Physiol. Psychol. 88:1975;534-541.
219. Seligman M.E., Rosellini R.A., Kozak M.J. Learned helplessness in the rat: Reversibility, time course, immunization, and reversibility. J. Comp. Physiol. Psychol. 88:1975;542-547.
220. Serova L., Sabban E.L., Zangen A., Overstreet D.H., Yadid G. Altered gene expression for catecholamine biosynthetic enzymes and stress response in rat genetic model of depression. Brain Res. Mol. Brain Res. 63:1998;133-138.
221. Shiromani P.J., Overstreet D., Levy D., Goodrich C.A., Campbell S.S., Gillin J.C. Increased REM sleep in rats selectively bred for cholinergic hyperactivity. Neuropsychopharmacology. 1:1988;127-133.
222. Sigg E.B., Hill R.T. The effect of imipramine on central adrenergic mechanisms. Brill H. Neuro-psycho-pharmacology. 1967;367-372 Excerpta Medica, Amsterdam.
223. Simpson D.M., Annau Z. Behavioral withdrawal following several psychoactive drugs. Pharmacol. Biochem. Behav. 7:1977;59-64.
224. Spanagel R., Herz A., Shippenberg T.S. Modulation of the mesolimbic dopaminergic system by β-endorphin-(1-27) as assessed by microdialysis. Eur. J. Pharmacol. 200:1991;319-324.
225. Stahl S.M. Essential Psychopharmacology. 1996;Cambridge University Press, New York, NY.
226. Stahl S.M. Psychopharmacology of Antidepressants. 1997;Martin Dunitz Press, London, UK.
227. Stahl S.M. Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. J.Clin. Psychiatry. 59 Suppl 18:1998;23-29.
228. Stahl S.M. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J. Affect. Disord. 51:1998;215-235.
229. Stahl S.M. Basic psychopharmacology of antidepressants. Part 1: Antidepressants have seven distinct mechanisms of action. J. Clin. Psychiatry. 59:(Suppl.):1998;5-14.
230. Stahl S.M., Woo D.J., Mefford I.N., Berger P.A., Ciaranello R.D. Hyperserotonemia and platelet serotonin uptake and release in schizophrenia and affective disorders. Am. J. Psychiatry. 140:1983;26-30.
231. Stanley M., Virgilio J., Gershon S. Tritiated imipramine binding sites are decreased in the frontal cortex of suicides. Science. 216:1982;1337-1339.
232. Stimmel G.L., Escobar J.I. Antidepressants in chronic pain: a review of efficacy. Pharmacotherapy. 6:1986;262-267.
233. Stokes P.E., Pick G.R., Stoll P.M., Nunn W.D. Pituitary-adrenal function in depressed patients: resistance to dexamethasone suppression. J. Psychiatr. Res. 12:1975;271-281.
234. 3H -imipramine binding and serotonin uptake in depressed patients. Life Sci. 36:1985;795-799.
235. Todrick A., Tait A.C., Marshell E.F. Blood platelet 5-hydroxytryptamine levels in psychiatric patients. Br. J. Psychiatry. 106:1960;884-890.
236. Tseng L.F., Wang Q. Forebrain sites differentially sensitive to b-endorphin and morphine for analgesia and release of Met-enkephalin in the pentobarbital-anesthetized rat. J. Pharmacol. Exp. Ther. 261:1992;1028-1036.
237. Tuomisto J., Tukianen E. Decreased uptake of 5-hydroxytryptamine in blood platelets from depressed patients. Nature. 262:1976;596-598.
238. Ueki S. Mouse-killing behaviour (muricide) in the rat and the effect of antidepressants. Langer S.Z., Takahashi R., Segawa T., Briley M. New Vistas in Depression. 1982;187-194 Pergamon Press, New York.
239. Uzunova V., Sheline Y., Davis J.M., Rasmusson A., Uzunov D.P., Costa E., Guidotti A. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc. Natl. Acad. Sci. USA. 95:1998;3239-3244.
240. van Praag H.M. Biological suicide research: outcome and limitations. Biol. Psychiatry. 21:1986;1305-1323.
241. van Praag H.M., Asnis G.M., Kahn R.S., Brown S.L., Korn M., Friedman J.M., Wetzler S. Monoamines and abnormal behaviour. A multi-aminergic perspective. Br. J. Psychiatry. 157:1990;723-734.
242. von Knorring L., Perris C., Eisemann M., Eriksson U., Perris H. Pain as a symptom in depressive disorders. Part II: Relationship to personality traits as assessed by means of KSP. Pain. 17:1983;377-384.
243. von Knorring L., Perris C., Oreland L., Eisemann M., Eriksson U., Perris H. Pain as a symptom in depressive disorders and its relationship to platelet monoamine oxidase activity. J. Neural Transm. 60:1984;1-9.
244. 3H -imipramine binding, 5-HT uptake and 5-HT content in major depressive disorder. J. Affect. Disord. 20:1990;101-113.
245. Wagner H.R., Hall T.L., Cote I.L. The applicability of inescapable shock as a source of animal depression. J. Gen. Psychol. 96:1977;313-318.
246. Wallis E., Overstreet D.H., Crocker A.D. Selective breeding for increased cholinergic function: increased serotonergic sensitivity. Pharmacol. Biochem. Behav. 31:1988;345-350.
247. Wang Q., Mao L.M., Han J.S. Characterization of inhibition of spinal nociceptive reflex by stimulation of the arcuate nucleus of the hypothalamus in the pentobarbital-anesthetized rat. Pain. 41:1990;101-108.
248. Weiss J.M. Effects of coping responses on stress. J. Comp. Physiol. Psychol. 65:1968;251-260.
249. Weiss J.M., Cierpial M.A., West C.H. Selective breeding of rats for high and low motor activity in a swim test: toward a new animal model of depression. Pharmacol. Biochem. Behav. 61:1998;49-66.
250. Weissman M.M., Leaf P.J., Tischler G.L., Blazer D.G., Karno M., Bruce M.L., Florio L.P. Affective disorders in five United States communities. Psychol. Med. 18:1988;141-153.
251. West C.H., Weiss J.M. Effects of antidepressant drugs on rats bred for low activity in the swim test. Pharmacol. Biochem. Behav. 61:1998;67-79.
252. West C.H., Bonsall R.W., Emery M.S., Weiss J.M. Rats selectively bred for high and low swim-test activity show differential responses to dopaminergic drugs. Psychopharmacology (Berl.). 146:1999;241-251.
253. West C.H., Boss-Williams K.A., Weiss J.M. Motor activation by amphetamine infusion into nucleus accumbens core and shell subregions of rats differentially sensitive to dopaminergic drugs. Behav. Brain Res. 98:1999;155-165.
254. Wheatley D.P., van Moffaert M., Timmerman L., Kremer C.M. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-fluoxetine study group. J. Clin. Psychiatry. 59:1998;306-312.
255. Whybrow P.G., Akiskal H.S., McKinney W.T. Mood Disorders: Toward a New Psychobiology. 1984;Plenum Press, New York.
256. Willner P. The validity of animal models of depression. Psychopharmacology (Berl.). 83:1984;1-16.
257. Willner P. Validation criteria for animal models of human mental disorders: learned helplessness as a paradigm case. Prog. Neuropsychopharmacol. Biol. Psychiatry. 10:1986;677-690.
258. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berl.). 134:1997;319-329.
259. Wise R.A. Neurobiology of addiction. Curr. Opin. Neurobiol. 6:1996;243-251.
260. Yadid G. The need for cautiously extrapolating results obtained with normal animals (healthy individuals) to depressed ones. J. Neurochem. 70:1998;2642-2642.
261. Yadid G., Pacak K., Kopin I.J., Goldstein D.S. Endogenous serotonin stimulates striatal dopamine release in conscious rats. J. Pharmacol. Exp. Ther. 270:1994;1158-1165.
262. Young S.N., Smith S.E., Pihl R.O., Ervin F.R. Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology (Berl.). 87:1985;173-177.
263. Young E.A., Watson S.J., Kotun J., Haskett R.F., Grunhaus L., Murphy-Weinberg V., Vale W., Rivier J., Akil H. b-Lipotropin-β-endorphin response to low-dose ovine corticotropin releasing factor in endogenous depression. Preliminary studies. Arch. Gen. Psychiatry. 47:1990;449-457.
264. Zacharko R.M., Bowers W.J., Kokkinidis L., Anisman H. Alteration of intracranial self-stimulation in mice following inescapable stress. Soc. Neurosci. Abstr. 8:1982;898.
265. Zakarian S., Smyth D.G. Distribution of b-endorphin-related peptides in rat pituitary and brain. Biochem. J. 202:1982;561-571.
266. Zangen A., Nakash R., Overstreet D., Yadid G. Absence of serotonin-dopamine interaction in a rat model of depression. Biol. Psychiatry. 43:1998;107.
267. Zangen A., Nakash R., Overstreet D., Yadid G. Impaired response of β-endorphin to serotonin stimulation in the nucleus accumbens of a rat model of depression. The 5th Annual Meeting of the ISBP, Kfar Giladi, Israel :1999;. (Abstract).
268. Zangen A., Nakash R., Yadid G. Serotonin-mediated increases in the extracellular levels of beta-endorphin in the arcuate nucleus and nucleus accumbens: a microdialysis study. J. Neurochem. 73:1999;2569-2574.
269. Zangen A., Overstreet D.H., Yadid G. High serotonin and 5-hydroxyindoleacetic acid levels in limbic brain regions in a rat model of depression: normalization by chronic antidepressant treatment. J. Neurochem. 69:1997;2477-2483.
270. Zangen A., Overstreet D.H., Yadid G. Increased catecholamine levels in specific brain regions of a rat model of depression: normalization by chronic antidepressant treatment. Brain Res. 824:1999;243-250.